DBV Technologies (NASDAQ:DBVT) Now Covered by Analysts at StockNews.com

Analysts at StockNews.com began coverage on shares of DBV Technologies (NASDAQ:DBVT) in a report released on Thursday. The brokerage set a “hold” rating on the stock.

Several other equities analysts have also weighed in on the company. JMP Securities lifted their price objective on DBV Technologies from $4.00 to $5.00 and gave the company a “market outperform” rating in a research note on Wednesday, July 31st. HC Wainwright reaffirmed a “buy” rating and issued a $5.00 price objective on shares of DBV Technologies in a research note on Thursday, August 1st.

DBV Technologies Trading Up 2.5 %

Shares of NASDAQ:DBVT opened at $0.75 on Thursday. The stock’s 50-day moving average price is $0.87 and its two-hundred day moving average price is $1.11. DBV Technologies has a 12-month low of $0.50 and a 12-month high of $2.92. The firm has a market cap of $72.23 million, a price-to-earnings ratio of -0.89 and a beta of 0.68.

DBV Technologies (NASDAQ:DBVT) last issued its quarterly earnings results on Tuesday, July 30th. The company reported ($0.34) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.26) by ($0.08). DBV Technologies had a negative return on equity of 74.41% and a negative net margin of 638.21%. The business had revenue of $1.16 million during the quarter, compared to analyst estimates of $1.42 million. During the same period in the previous year, the business posted ($0.26) earnings per share. As a group, research analysts forecast that DBV Technologies will post -1.43 earnings per share for the current fiscal year.

Hedge Funds Weigh In On DBV Technologies

A hedge fund recently raised its stake in DBV Technologies stock. Yiheng Capital Management L.P. lifted its stake in shares of DBV Technologies S.A. (NASDAQ:DBVT) by 6.2% during the 1st quarter, according to the company in its most recent 13F filing with the SEC. The firm owned 5,568,909 shares of the company’s stock after buying an additional 327,345 shares during the quarter. DBV Technologies accounts for approximately 0.2% of Yiheng Capital Management L.P.’s holdings, making the stock its 15th largest holding. Yiheng Capital Management L.P. owned about 2.89% of DBV Technologies worth $4,172,000 at the end of the most recent reporting period. Institutional investors own 71.74% of the company’s stock.

About DBV Technologies

DBV Technologies SA, a clinical-stage biopharmaceutical company, engages in the research and development of epicutaneous immunotherapy products. Its product pipeline comprising Viaskin Peanut, an immunotherapy product, which has completed Phase 3 clinical trial for the treatment of peanut allergies; and Viaskin Milk which is in Phase 1/2 clinical trial for the treatment of immunoglobulin E (IgE) mediated or cow's milk protein allergy and eosinophilic esophagitis.